GlassScriptPhysician profile
Gwendolyn H Wright
NPI 1467832246
$46,813.98
in general payments reported to CMS, 2019-2025
30 companies · $25K in 2025
The $25K reported for 2025 was more than what 99% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,240 · 2022: $3,219 · 2023: $5,529 · 2024: $12K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $8,869 · Travel and Lodging: $7,143 · Consulting Fee: $5,616 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,614.50 |
| Food and Beverage | $8,869.23 |
| Travel and Lodging | $7,143.00 |
| Consulting Fee | $5,616.00 |
| Education | $111.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14,579.80 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13,545.78 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $11,216.85 | 2021-2025 | |
| Genzyme Corporation | $3,113.94 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $1,254.18 | 2024-2025 | Bylvay, Iqirvo |
| Janssen Biotech, INC. | $501.92 | 2023-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $338.35 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $329.26 | 2023-2025 | Epclusa |
| Pfizer INC. | $297.39 | 2024-2025 | |
| Regeneron Pharmaceuticals, INC. | $231.95 | 2024-2025 | Dupixent |
| Ardelyx, INC. | $210.74 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $165.47 | 2024-2025 | |
| Lilly USA, LLC | $138.37 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $99.84 | 2023 | |
| Phathom Pharmaceuticals, INC. | $92.05 | 2024 | Voquezna |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $83.88 | 2025 | Rezdiffra |
| Celltrion USA INC. | $83.24 | 2024-2025 | Vegzelma |
| Janssen Scientific Affairs, LLC | $76.28 | 2024 | |
| Merz North America, INC. | $73.77 | 2022-2023 | Xeomin |
| Organon LLC | $63.09 | 2023 | Renflexis, Hadlima |
| Aimmune Therapeutics, INC. | $60.55 | 2024-2025 | Zenpep |
| Celgene Corporation | $53.38 | 2022-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $52.57 | 2023-2024 | Rebyota |
| Ironwood Pharmaceuticals, INC | $47.77 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $24.40 | 2021 | |
| Alnylam Pharmaceuticals INC. | $18.66 | 2025 | Givlaari |
| Novo Nordisk INC | $17.13 | 2025 | Wegovy |
| Intra-Sana Laboratories | $16.34 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Braintree Laboratories, INC. | $13.53 | 2023 | Sutab, Suflave |
| Evoke Pharma, INC. | $13.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gwendolyn Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.